Acurx Pharmaceuticals Inc., a late-stage biopharmaceutical company specializing in developing a new class of antibiotics, has announced a warrant inducement agreement with a holder of existing warrants. This agreement involves the exercise of warrants to purchase up to 4,445,435 shares of common stock at a reduced exercise price of $0.675 per share, generating gross proceeds of approximately $2.67 million. In exchange for this exercise, the investors received G-1 and G-2 warrants to purchase up to 8,890,870 shares of common stock. The G-1 Warrants are immediately exercisable at an exercise price of $0.425 per share, while the G-2 Warrants will become exercisable upon shareholder approval. The company plans to use the net proceeds for working capital and general corporate purposes. The transaction is expected to close by June 20, 2025, pending customary closing conditions.